Crystal Structures of Candida albicans Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility of Active Site Loop Residues Critical for Ligand Potency and Selectivity

Chemical Biology and Drug Design

Volumn 78, Issue 4, 2011, Pages 505-512

  Paulsen, Janet L ^a   Bendel, Stephen D ^a   Anderson, Amy C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antifolate; Candida albicans; Candida glabrata; DHFR; Structure based drug design; X ray crystallography

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; LIGAND; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HYDROPHOBICITY; IC 50; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; FOLIC ACID ANTAGONISTS; HUMANS; LIGANDS; MODELS, MOLECULAR; PARGYLINE; PROTEIN BINDING; TETRAHYDROFOLATE DEHYDROGENASE;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA;

EID: 80052636582     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01169.x     Document Type: Article

References (25)

1. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis;29:239-244.
2. Pfaller M.A., Diekema D.J. (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol;42:4419-4431.
3. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., Phelan M. et al. (2004) Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol;42:1519-1527.
4. Zilberberg M., Shorr A., Kollef M. (2008) Secular trends in candidemia related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol;29:978-980.
5. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P. (2002) National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis;35:627-630.
6. Pfaller M.A., Messer S.A., Boyken L., Tendolkar S., Hollis R.J., Diekema D.J. (2004) Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol;42:3142-3146.
7. Pfaller M.A., Diekema D.J. (2004) International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect;10(Suppl 1):11-23.
8. Bennett J.E., Izumikawa K., Marr K.A. (2004) Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother;48:1773-1777.
9. Sanglard D., Ischer F., Calabrese D., Majcherczyk P.A., Bille J. (1999) The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother;43:2753-2765.
10. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., Herwaldt L., Pfaller M., Diekema D. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis;37:1172-1177.
11. Fleming G.F., Schilsky R.L. (1992) Antifolates: the next generation. Semin Oncol;19:707-719.
12. Roth B., Rauckman B.S., Ferone R., Baccanari D.P., Champness J.N., Hyde R.M. (1987) 2, 4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3, 5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes. J Med Chem;30:348-356.
13. Salter A.J. (1982) Trimethoprim-sulfamethoxazole: an assessment of more than 12years of use. Rev Infect Dis;4:196-236.
14. Plowe C., Kublin J., Kamwendo D., Mukadam R., P C., Molyneux M., Taylor T., Terrie E. (2004) Sustained efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10year as first-line treatment; five-year prosepctive study. Brit Med J;328:545-548.
15. Paulsen J.L., Liu J., Bolstad D.B., Smith A.E., Priestley N.D., Wright D.L., Anderson A.C. (2009) In vitro biological activity and structural analysis of 2, 4-diamino-5-(2'-arylpropargyl)pyrimidine inhibitors of Candida albicans. Bioorg Med Chem;17:4866-4872.
16. Whitlow M., Howard A.J., Stewart D., Hardman K.D., Chan J.H., Baccanari D.P., Tansik R.L., Hong J.S., Kuyper L.F. (2001) X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor. J Med Chem;44:2928-2932.
17. Liu J., Bolstad D.B., Smith A.E., Priestley N.D., Wright D.L., Anderson A.C. (2008) Structure-guided development of efficacious antifungal agents targeting Candida glabrata dihydrofolate reductase. Chem Biol;15:990-996.
18. Liu J., Bolstad D.B., Smith A.E., Priestley N.D., Wright D.L., Anderson A.C. (2009) Probing the active site of Candida glabrata dihydrofolate reductase with high resolution crystal structures and the synthesis of new inhibitors. Chem Biol Drug Des;73:62-74.
19. Otwinowski Z., Minor W. (1997) Processing of X-ray diffraction data collected in oscillation mode. In: Carter C.J., Sweet R., editors. Methods in Enzymology. New York, USA: Academic Press; p. 307-326.
20. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. (2007) Phaser crystallographic software. J Appl Crystallogr;40:658-674.
21. Emsley P., Cowtan K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr;2004:60.
22. Murshudov G.N., Vagin A.A., Dodson E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr;53:240-255.
23. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr;26:283-291.
24. Whitlow M., Howard A.J., Stewart D., Hardman K.D., Kuyper L.F., Baccanari D.P., Fling M.E., Tansik R.L. (1997) X-ray crystallographic studies of Candida albicans dihydrofolate reductase. High resolution structures of the holoenzyme and an inhibited ternary complex. J Biol Chem;272:30289-30298.
25. Algul O., Paulsen J.L., Anderson A.C. (2011) 2, 4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition. J Mol Graph Model;29:608-613.